Ciprofloxacin

Selected oral and IV labels cover adult susceptible skin, bone/joint, complicated intra-abdominal infection with metronidazole, bacterial prostatitis, lower respiratory and urinary infections, sinusitis, anthrax postexposure and plague. Oral labeling additionally includes specified infectious diarrhea, typhoid fever and uncomplicated cervical/urethral gonorrhea. IV additionally labels nosocomial pneumonia and febrile neutropenia with piperacillin. Pediatric systemic uses are limited: E. coli cUTI/pyelonephritis at ages 1–17; anthrax postexposure and plague from birth through 17. It is not a first-choice pediatric drug or a first-choice agent for pneumococcal pneumonia.

Reserve systemic ciprofloxacin for uncomplicated cystitis, acute bronchitis exacerbation and acute sinusitis when no alternative treatment options exist. Culture, susceptibility and local resistance guide selection. The oral label retains a 250 mg single-dose gonorrhea regimen, but CDC guidance does not recommend routine empiric fluoroquinolone treatment; ceftriaxone is preferred. Its selected asymptomatic gyrA-susceptible exception uses 500 mg orally once under the CDC drug-allergy pathway, not the older label dose.

Selected ophthalmic solution 0.3% treats susceptible bacterial conjunctivitis and corneal ulcers; Ciloxan ointment 0.3% labels bacterial conjunctivitis, not the solution’s ulcer regimen. Genus and Cetraxal otic solution 0.2% treat acute otitis externa due to susceptible P. aeruginosa or S. aureus at ≥1 year. They are not the ciprofloxacin/steroid combinations catalogued separately.

Current FDA records list Dr. Reddy’s total 1000 mg ER product as prescription and its total 500 mg product as discontinued. Cipro XR, Proquin XR and Otiprio appear in the discontinued list. The current generic ER PI was not retrieved; the publicly attached 2021 Cipro XR reference label is not presented as that generic’s current directions. Do not interchange IR and ER milligram-for-milligram or infer a regimen from discontinued products. ER actionable dosing is outside this verified profile until the current PI is obtained.

Use susceptibility and current infection-specific guidance; labeled durations are not automatic treatment targets.

Infuse each IV dose over 60 minutes, never rapid IV push. Selected 2 mg/mL premixed bags require no dilution; check bag integrity and solution clarity.

IDSA 2025 conditionally favors 5–7 days of an effective fluoroquinolone in clinically improving adult cUTI/pyelonephritis, counted from the first effective treatment day. Studies often excluded severe sepsis, catheters, immune compromise, CKD, abscess, obstruction, prostatitis or urologic procedures; these require individualized duration. This does not shorten pediatric label regimens or chronic prostatitis treatment by default.

Use only the specified pediatric indications; renal dysfunction needs specialist assessment, not extrapolation of adult tables.

Adult IR oral: CrCl >50 mL/min uses usual dosing; 30–50 uses 250–500 mg every 12 hours; 5–29 uses 250–500 mg every 18 hours; hemodialysis/peritoneal dialysis uses 250–500 mg every 24 hours after dialysis. Carefully monitored severe infection may use a 750 mg unit dose at the stated adjusted intervals. Selected IV label differs: CrCl >30 uses usual dosing; 5–29 uses 200–400 mg every 18–24 hours; no separate dialysis schedule is supplied in that table. Pediatric CrCl <50 mL/min/1.73 m² adjustment is unestablished. Stable chronic cirrhosis did not significantly change PK; acute hepatic insufficiency is unstudied. No topical organ adjustment formula is provided.

Take IR with or without food, at least 2 hours before or 6 hours after cation-containing products. Avoid dairy or calcium-fortified juice alone; a meal containing them is allowed. If <6 hours remain before the next IR dose, skip a missed dose; never double. Cipro 250 mg and 500 mg tablets are functionally scored and can be halved. Suspension concentrations are 250 mg/5 mL and 500 mg/5 mL: verify the concentration before measuring. Pharmacist preparation combines supplied microcapsules and diluent without added water. Shake about 15 seconds each use, measure with the co-packaged spoon and do not chew microcapsules. No feeding/NG tube administration.

Eye solution ulcer treatment requires close ophthalmic supervision: two drops every 15 minutes for first 6 hours, then every 30 minutes for the remainder of day 1; two drops hourly on day 2; two drops every 4 hours on days 3–14. Continue beyond 14 days only if the prescriber determines re-epithelialization is incomplete. Conjunctivitis solution: 1–2 drops every 2 hours while awake for 2 days, then every 4 hours while awake for 5 days. Ointment: ½-inch ribbon three times daily for 2 days, then twice daily for 5 days. Otic 0.2%: one 0.25 mL container in each affected ear twice daily about 12 hours apart for 7 days; warm in hands ≥1 minute, maintain ear-up position ≥1 minute and discard used containers.

Systemic oral/IV: hypersensitivity to ciprofloxacin, other quinolones or ingredients; concomitant tizanidine is contraindicated. Ophthalmic solution/ointment: ciprofloxacin or ingredient hypersensitivity, with other quinolone allergy potentially contraindicating use. Selected otic labels contraindicate ciprofloxacin hypersensitivity. Do not transfer the systemic tizanidine contraindication into a topical label as though it were explicitly listed there.

Current selected systemic oral and IV labels carry boxed warnings for serious disabling tendon, neuropathy and CNS effects, and exacerbation of myasthenia gravis; selected less serious indications are reserved for patients without alternatives. Selected ophthalmic and otic labels have no boxed warning. This is a route-specific distinction, not a claim that topical products lack serious allergy risk.

Systemic reactions include nausea, diarrhea, vomiting, rash and abnormal liver tests; IV can cause local venous reactions. Eye products may burn, sting or cause discomfort; white corneal precipitate can occur with intensive ulcer drops and does not automatically require stopping. Ear products may cause local pain, itching, fungal superinfection or headache. Systemic overdose can injure kidneys; obtain urgent medical/Poison Help guidance, supportive care and renal monitoring. Dialysis removes <10%. Do not induce vomiting at home. Eye-solution excess can be flushed with warm tap water per label.

Specific ophthalmic interaction studies were not conducted. Topical systemic exposure is low, and the labels discuss systemic quinolone interactions without establishing the same magnitude after eye or ear use. Do not assume oral chelation or systemic dosing adjustments apply to a topical regimen.

Systemic observational pregnancy data have not identified a clear drug-associated risk, but cannot establish absence of risk. Current oral/IV labels advise avoiding breastfeeding during treatment and for 2 days afterward for most indications, or pumping/discarding; anthrax exposure can justify a different risk-benefit assessment. Monitor a breastfed infant for diarrhea or candidiasis if breastfeeding continues under advice. Eye milk-transfer data are unknown and labels advise caution; otic labels call for a nursing-versus-treatment decision. Do not assign one universal lactation rule across routes.

Systemic cUTI/pyelonephritis is labeled at 1–17 years, and anthrax/plague from birth–17; routine pediatric use is limited by musculoskeletal reactions. Selected Sandoz ophthalmic SOLUTION establishes use at all ages including neonates; Ciloxan OINTMENT is unestablished below 2. Genus/Cetraxal ear solution is unestablished below 1 year. Older systemic users have greater tendon, QT, aortic and renal risks; age alone needs no change with normal renal function.

Use the exact oral versus IV renal instructions above. Pediatric moderate/severe renal adjustments and acute hepatic-insufficiency PK are unestablished. Stable chronic cirrhosis data do not justify ignoring liver-toxicity symptoms. Topical labels do not specify a quantitative renal/hepatic algorithm; no one is invented here.

Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV. Resistance can arise through target mutations, reduced permeability or efflux; local susceptibility and the labeled infection/pathogen matter. Broad in-vitro lists do not establish efficacy for unstudied infections.

Oral IR absorption

About 70% bioavailability; peak about 1–2 hours. Suspension/tablet equivalents are dose- and concentration-specific.

Systemic distribution/elimination

About 20–40% protein bound; half-life about 4 hours with normal renal function; roughly 40–50% oral dose recovered unchanged in urine.

Metabolism and interaction

Partial metabolism; clinically important CYP1A2 inhibition.

Eye and ear exposure

Ophthalmic solution measured peaks <5 ng/mL. Ointment human absorption was not measured directly; otic label anticipates low levels rather than reporting a measured systemic study.

• Confirm infection, susceptibilities, route and renal function before selecting dose; review resistance and narrow therapy when results arrive.
• Monitor tendon, neuropathy, neuropsychiatric, allergy and liver symptoms; assess QT/electrolyte risk, glucose and interacting-drug levels when relevant.
• For prolonged systemic therapy, periodically assess renal, hepatic and blood-cell function. Review hydration and renal changes.
• Reassess persistent or significant diarrhea; it can begin after treatment ends.
• Ophthalmic ulcers require examination and healing follow-up; otic infection not improved after one week may need culture and reassessment.

• Verify the prescribed route and formulation; do not replace IR with ER or use ear solution in an eye. Read the systemic Medication Guide.
• Separate oral IR from mineral products; verify suspension concentration, shake 15 seconds and do not double missed doses. Follow the prescribed course unless instructed to stop for adverse symptoms.
• Stop systemic medicine and promptly contact the clinician for tendon pain, tingling/numbness, serious mental changes or hypoglycemia; breathing problems or severe chest/back/abdominal pain need emergency care.
• Limit UV exposure and maintain fluid intake appropriate to medical conditions. Report persistent watery/bloody diarrhea.
• Avoid contaminating eye applicators and contact lens use during bacterial conjunctivitis. Ear containers are single-use; warm in hands and maintain ear-up positioning.

Form and strength

Immediate-release film-coated tablet · 500 mg

Appearance

Slightly yellowish, capsule shaped and functionally scored

Imprint

BAYER on one side; CIP 500 on reverse

Example NDC

50419-754-01 · 100 tablets

Selected Cipro IR tablets: 250 and 500 mg; oral suspensions: 250 mg/5 mL and 500 mg/5 mL. Sagent IV premix: 200 mg/100 mL and 400 mg/200 mL in 5% dextrose. Selected ophthalmic solution and ointment: 0.3%. Genus/Cetraxal single-use otic solution: 0.2%, delivering 0.5 mg in 0.25 mL. Current FDA ER status is verified separately; current generic dispensing directions are not supplied here. Steroid combinations and discontinued Otiprio are excluded.

Cipro tablets: 20–25°C, excursions 15–30°C. Suspension components: below 25°C with permitted excursions; mixed suspension: 25°C with permitted excursions for 14 days, never freeze, discard after the course. IV bags: 5–25°C, protect light and freezing; discard unused portion. Selected eye solution/ointment: 2–25°C; solution protected from light. Ear solution: 15–25°C, unused containers in pouch away from light, discard used containers. Follow exact manufacturer packaging.